AZN: financial statements from SEC — TradeAlmanac

AZN

AstraZeneca PLC: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	58.74bn	54.07bn	45.81bn	44.35bn
Cost of revenue	10.63bn	10.21bn	8.27bn	12.39bn
Gross profit	48.11bn	43.87bn	37.54bn	31.96bn
Research and development	14.23bn	13.58bn	10.94bn	9.76bn
Selling, general and administrative	19.93bn	19.98bn	19.22bn	18.42bn
Operating income	13.74bn	10.00bn	8.19bn	3.76bn
Pre-tax income	12.40bn	8.69bn	6.90bn	2.50bn
Income tax	2.17bn	1.65bn	938m	−792m
Net income	10.23bn	7.04bn	5.96bn	3.29bn
Earnings per share	6.60	4.54	3.84	2.12
Earnings per share, diluted	6.54	4.50	3.81	2.11
Weighted average shares	1.55bn	1.55bn	1.55bn	1.55bn

Balance sheet

Metric	Aug 18, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash and equivalents	—	5.71bn	5.49bn	5.84bn	6.17bn	—
Receivables	—	15.18bn	12.97bn	12.13bn	10.52bn

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating cash flow	14.58bn	11.86bn	10.35bn	9.81bn
Capital expenditure	2.81bn	1.92bn	1.36bn	1.09bn
Investing cash flow	−6.81bn	−7.98bn	−4.06bn	−2.96bn
Dividends paid

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)